JVM Co

JVM Co EBIT Growth

The Year-over-Year EBIT Growth of JVM Co (054950.KQ) as of Nov 4, 2026 is 8.48 %. In the previous year, Year-over-Year EBIT Growth was 3.04 % — a change of 179.18% (higher).

EBIT Growth

8.48 %

YoY

179.18%

Last updated:

Year-over-Year EBIT Growth of JVM Co is 2025 8.48 % . Year-over-Year EBIT Growth of JVM Co was 2024 3.04 % . It decreases by 179.18% higher compared to the previous year.

The JVM Co EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
-21.08 KRW
Jan 1, 2019
-36.02 KRW
Jan 1, 2020
117.31 KRW
Jan 1, 2021
-13.43 KRW
Jan 1, 2022
78.76 KRW
Jan 1, 2023
49.04 KRW
Jan 1, 2024
3.04 KRW
Jan 1, 2025
8.48 KRW
The JVM Co EBIT Growth history
YEAREBIT GrowthYoY
8.48 %+179.18%
3.04 %-93.81%
49.04 %-37.74%
78.76 %-686.35%
-13.43 %-111.45%
117.31 %-425.68%
-36.02 %+70.90%
-21.08 %+40,382.17%
-0.05 %-100.03%
148.96 %-345.19%
-60.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JVM Co Stock analysis

What does JVM Co do? JVM Co., Ltd. manufactures pharmacy automation systems under the brand JVM, targeting domestic and overseas markets. The company's primary products include automatic tablet dispensing and packaging systems (ATDPSs), automatic tablet classification and packing machines available in slide, box, and drum types, total safety solutions, automatic medication vision inspection systems (VIZENs), automatic package cutting and winding systems (WIZERs), and automatic medication sorting and control systems (AccuPharm). These products are sold to customers in the pharmaceutical and healthcare sectors seeking efficient automation solutions for medication handling and safety. The firm generates revenue through the sale of its branded automation systems, with a focus on domestic distribution and international markets. JVM's product portfolio addresses key operational needs in pharmacy settings, including dispensing, classification, inspection, and sorting of medications, ensuring compliance with safety standards while improving workflow efficiency. The company's offerings are designed to meet the demands of healthcare providers and pharmaceutical manufacturers requiring advanced automation technologies. JVM's business model centers on providing comprehensive automation solutions for pharmacy operations, leveraging its established brand JVM to differentiate its products in the market. By offering a wide range of specialized systems, the company caters to both domestic and international clients seeking reliable, high-quality automation equipment for medication management and safety protocols. JVM Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JVM Co stock

Year-over-Year EBIT Growth of JVM Co is 8.48 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth JVM Co since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's JVM Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — JVM Co

All Key Metrics — JVM Co